the aid library

LIST OPTIONS

Filter

12652

Preparedness, prevention and control of COVID-19 in prisons and other places of detention: interim guidance, 8 February 2021
recommended

C. Ferreira-Borges; Dr. J. Breda; M. Dara; et al. World Health Organization (Europe) (2021) C_WHO

Updated guidance. The guidance provides useful information to staff working in prisons, as well as to health and prison authorities, explaining how to prevent and address a potential outbreak of COVID-19. In addition, it aims to protect the health and well-being of all those who live and work in, an... more

Download (372)

View PDF (424)

Practical Manual for Implementation ofthe National Infection Prevention and Control Strategic Framework

Department of Health, Republic of South Africa (2020) C1

Download (554)

View PDF (714)

Liberia: Vehicle Management: County-Level Policy and Procedure Manual (DMSS 2009)

Ministry of Health and Social Welfare, Liberia; USAID BASICS Project (2009) C1

Download (408)

View PDF (586)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (227)

View PDF (455)

Preventing and mitigating COVID-19 at work

World Health Organization WHO (2021) C_WHO

Workplaces outside of healthcare facilities can be also settings for transmission of COVID-19. Outbreaks of COVID-19 has been reported in various types of workplaces and job categories. All workers should be protected from acquiring COVID-19 because of their work. The prevention of COVID-19 in ... more

Download (247)

View PDF (429)

Antipsychotics and mood stabilizers in individuals with bipolar mania

World Health Organization WHO (2015) C_WHO

Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe

Download (255)

View PDF (392)

Pharmacological and nonpharmacological interventions for children with attention-deficit hyperactivity disorder (ADHD)

World Health Organization (2012) C_WHO

Q7: What is the effectiveness, safety and role of pharmacological and non-pharmacological interventions, within non- specialist health care for children with a diagnosis of Attention-deficit hyperactivity disorder (ADHD)?

Download (230)

View PDF (327)

Treatment - Paediatric HIV Care and Treatment

World Health Organization; UNAIDS; Unicef (2009) C_WHO

Working Document - Updated -February 2009

Download (1348)

View PDF (2247)

Definitions and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia

World Health Organization; International Diabetes Federation (2006) C_WHO

Download (212)

View PDF (327)

Preventing injuries and violence: an overview

World Health Organisation (WHO) (2022) C_WHO

This brief advocacy document highlights the burden, risks and prevention of injuries and violence, which took the lives of 4.4 million people in 2019 and constitute 8% of all deaths. Among the injury-related causes of death include road traffic crashes, drowning, falls, burns, poisoning and violence... more

Download (226)

View PDF (291)

Occupational stress, burnout and fatigue

World Health Organisation (WHO) (2022) C_WHO

Infogaphic

Download (555)

View PDF (1495)

Botswana: Country Data Profile on the Pharmaceutical Situation in the Southern African Development Community (SADC)

John Botsang World Health Organisation (WHO) (2009) C2

Download (259)

View PDF (338)

Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

World Health Organization WHO (2021) C_WHO

The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020), on potential mechanisms of vertical transmission of infectious pathog... more

Download (1628)

View PDF (3005)

Specifications and quantities for efficient procurement of essential equipment and laboratory commodities for HIV

Francis Aboagye-Nyame, Heather Alexander, Zelalem Gizachew Belachew et al. World Health Organization (2015) C_WHO

Second Edition AIDS Medicines and diagnostics services July 2015

Download (681)

View PDF (654)

Review of Tuberculosis Prevention, Control and Care in Azerbaijan (Russian edition)

M. Dara, O. Gozalov, O. Javadli, et al. World Health Organization Europe (2013) C_WHO

11-17 April 2012 Оценка профилактики и борьбы с туберкулезом и противотуберкулезной помощи в Азербайджане 11–17 апреля 2012 г.

Download (313)

View PDF (317)

Improving the Quality of PrEP Implementation for Adolescent Girls and Young Women: An implementation brief to support programming in Eastern and Southern Africa

World Health Organization WHO, Regional Office of Africa; UNICEF (2021) C_WHO

Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers to access, uptake and use of traditional HIV prevention me... more

Download (107)

View PDF (79)

Practical and Precision Assessment Manual for Schistosomiasis
recommended

World Health Organization WHO, Regional Office of Africa (2024) C_WHO

A manual for impact assessments. The SCH Practical and Precision Assessment (SPPA) strategy is an evidence-based approach for conducting impact assessments for SCH. The SPPA was identified by programme managers and SCH experts from the African region as a feasible and sufficiently accurate approach ... more

Download (183)

View PDF (326)

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (987)

View PDF (1516)

Guidelines for the production, control and regulation of snake antivenom immunoglobulins

World Health Organization (WHO) (2017) C_WHO

Replacement of Annex 2 of WHO Technical Report Series, No. 964... more

Download (545)

View PDF (1172)

Visual Impairment and Blindness 2010 (Fact Sheet)

World Health Organization (WHO) (2010) C_WHO

Preparedness, prevention and control of COVID-19 in prisons and other places of detention: interim guidance, 8 February 2021 recommended

Practical and Precision Assessment Manual for Schistosomiasis recommended

Preparedness, prevention and control of COVID-19 in prisons and other places of detention: interim guidance, 8 February 2021
recommended

Practical and Precision Assessment Manual for Schistosomiasis
recommended